Compounds > ciprofibrate

ciprofibrate and fluorodeoxyglucose f18

ciprofibrate has been researched along with fluorodeoxyglucose f18 in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
de Wit-Verheggen, VHW; Gemmink, A; Haas, J; Hesselink, MKC; Joris, PJ; Liénard, V; Montaigne, D; Nascimento, EBM; Phielix, E; Raiko, J; Schaart, G; Schrauwen, P; Schrauwen-Hinderling, VB; Staels, B; van de Weijer, T; Vanweert, F; Wierts, R; Wildberger, JE1

Trials

1 trial(s) available for ciprofibrate and fluorodeoxyglucose f18

ArticleYear
The tissue-specific metabolic effects of the PPARα agonist ciprofibrate in insulin-resistant male individuals: a double-blind, randomized, placebo-controlled crossover study.
    Obesity (Silver Spring, Md.), 2023, Volume: 31, Issue:10

    Topics: Cross-Over Studies; Fluorodeoxyglucose F18; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Muscle, Skeletal; PPAR alpha

2023